|Orexigen Therapeutics, Inc.|
3344 North Torrey Pines Court
United States - Map
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
|Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Michael A. Narachi M.S., M.B.A.,
Chief Exec. Officer, Pres and Director
|Mr. Joseph P. Hagan ,
Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
|Ms. Heather D. Turner J.D.,
Sr. VP, Gen. Counsel and Sec.
|Mr. Mark D. Booth ,
Chief Commercial Officer
|Dr. Preston S. Klassen M.D., M.H.S.,
Head of Global Contrave Program and Sr. VP of Product Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|